Balance Sheet
Cash Flow Statement
Cash from Discontinued OperationsCash from Discontinued OperationsCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Depreciation and Depletion (2019 - 2025)

Addex Therapeutics' Depreciation and Depletion history spans 7 years, with the latest figure at -$2.6 billion for Q2 2025.

  • On a quarterly basis, Depreciation and Depletion rose 96.71% to -$2.6 billion in Q2 2025 year-over-year; TTM through Jun 2025 was $2.8 billion, a 101.67% increase, with the full-year FY2025 number at $10218.3, down 96.56% from a year prior.
  • Depreciation and Depletion came in at -$2.6 billion for Q2 2025, down from $2.4 billion in the prior quarter.
  • The five-year high for Depreciation and Depletion was $272.8 billion in Q3 2024, with the low at -$269.8 billion in Q4 2024.
  • Historically, Depreciation and Depletion has averaged $203.9 million across 5 years, with a median of $91999.6 in 2021.
  • Peak annual rise in Depreciation and Depletion hit 194303126.57% in 2023, while the deepest fall reached 325276525.18% in 2023.
  • Year by year, Depreciation and Depletion stood at $89976.8 in 2021, then decreased by 12.73% to $78524.3 in 2022, then crashed by 325276525.18% to -$255.4 billion in 2023, then decreased by 5.61% to -$269.8 billion in 2024, then skyrocketed by 99.05% to -$2.6 billion in 2025.
  • Business Quant data shows Depreciation and Depletion for ADXN at -$2.6 billion in Q2 2025, $2.4 billion in Q1 2025, and -$269.8 billion in Q4 2024.